ped audio lecture-franz-tsc-4-1
DESCRIPTION
Esclerosis tuberosa o Epiloia. Aspectos de su presentación clínica, y de su repercusión en cerebro, riñón y pulmón.TRANSCRIPT
![Page 1: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/1.jpg)
Emerging Treatment Strategies for Tuberous Sclerosis Complex
David Neal Franz, MDDirector, Tuberous Sclerosis ClinicCincinnati Children’s Hospital Medical CenterCincinnati, Ohio
![Page 2: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/2.jpg)
Goals
• Describe the manifestations of tuberous sclerosis complex (TSC) in various organ systems and the most frequent causes of neurologic, renal, and pulmonary morbidity and mortality
• Review the molecular pathophysiology of TSC and how this forms the basis for novel therapeutic approaches
• Compare the rationale and initial clinical trial evidence for emerging treatment approaches for TSC
• Summarize ongoing clinical trials evaluating treatment approaches for TSC, including the goals of the trials, patient eligibility criteria, and other key factors
![Page 3: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/3.jpg)
Pan D, et al. Trends Cell Biol. 2004;14:78-85.
Clinical Manifestations of TSC
• Brain: cortical tubers, subependymal nodules, subependymal giant cell astrocytomas
• Eye: retinal hamartomas
• Heart: cardiac rhabdomyomas
• Kidney: benign angiomyolipomas, cysts, malignant angiomyolipomas, renal cell carcinoma
• Lung: lymphangioleiomyomatosis, multifocal micronodular pneumocyte hyperplasia
• Skin: hypomelanotic macules, shagreen patches, periungual or subungual fibromas, facial angiofibromas
• Behavior: mental retardation, autism, bipolar disorder
![Page 4: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/4.jpg)
Roach ES, Sparagana SP. J Child Neurol. 2004;19:643-649.
Clinical Diagnostic CriteriaMajor Features Minor FeaturesCortical tubers Multiple, randomly distributed
pits in dental enamel
Subependymal nodules Hamartomatous rectal polyps
Subependymal giant cell astrocytoma Bone cysts
Hypomelanotic macules (3 or more) Cerebral white matter radial migration lines
Shagreen patch (connective tissue nevus) Gingival fibromas
Facial angiofibromas or forehead plaque Nonrenal hamartoma
Multiple retinal nodular hamartomas Retinal achromic patch
Nontraumatic ungual or periungual fibromas “Confetti” skin lesions
Cardiac rhabdomyoma, single or multiple Multiple renal cysts
Pulmonary lymphangioleiomyomatosis and/or renal angiomyolipomas
![Page 5: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/5.jpg)
TSC: Onset of Symptoms
0 20 40 60 80
Lung
Skin
Cerebral
Renal
Cardiac
Age in Years
![Page 6: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/6.jpg)
Hypopigmented Macule and Shagreen Patch
![Page 7: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/7.jpg)
Facial Angiofibroma
![Page 8: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/8.jpg)
Periungual Fibroma
![Page 9: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/9.jpg)
Dental Pits and Gingival Fibromas
![Page 10: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/10.jpg)
Retinal Hamartomas and Achromic Patches
![Page 11: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/11.jpg)
Cardiac Rhabdomyoma
![Page 12: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/12.jpg)
Lymphangioleiomyomatosis (LAM)
![Page 13: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/13.jpg)
Renal Angiomyolipoma and Renal Cysts
![Page 14: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/14.jpg)
Angiomyolipoma
![Page 15: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/15.jpg)
Cerebral Manifestations of TSC
![Page 16: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/16.jpg)
Cortical Tuber
![Page 17: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/17.jpg)
Subependymal Nodules
![Page 18: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/18.jpg)
Neurologic/Behavioral Manifestations
• Seizures (90%)• Mental retardation and learning difficulties
(60%-70%)• Sleep disorders (60%)• Autism and behavioral difficulties (30%-50%)• Subependymal giant cell astrocytoma (15%-
20%)
![Page 19: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/19.jpg)
Seizures, Infantile Spasms, and Cognitive Outcome
• Infantile spasms correlated with increased risk for poor neurologic outcomea
a O’Callaghan FJ, et al. Arch Dis Child. 2004;89:530-533.b Goh S, et al. Neurology. 2005;65:235-238.
Clinical Variables Associated With Mental Retardation in Patients With TSC and Infantile Spasmsb
Variable Odds Ratio 95% CI P Value
Time from treatment initiation until clinical cessation
1.07 1.01-1.14 .018
Total duration of infantile spasms from clinical onset to cessation
1.09 1.03-1.15 .004
Poor control of other seizures after cessation of infantile spasms
17.76 3.47-129.1 .00004
![Page 20: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/20.jpg)
Infantile Spasms in TSC
• Vigabatrin is the treatment of choice in TSC– Risk for adverse effect on peripheral vision – As high as 95% response rate in TSCa
• Steroids are second-line treatment (adrenocorticotropic hormone or oral prednisone)
• Valproate, topiramate, clonazepam minimally effective as single agents but may have beneficial adjunctive use
aHancock EC, Osborne JP. J Child Neurol. 1999;14:71-74.
![Page 21: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/21.jpg)
Epilepsy in TSC
• About 90% of patients with TSC experience seizures• Virtually all seizure types have been reported (simple
partial, complex partial, generalized tonic-clonic, absence)
• Aggressive treatment is necessary to reduce risk for negative neurologic outcome (development, cognition, behavior)
![Page 22: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/22.jpg)
Surgical Outcome of Epilepsy Surgery in TSC
• Outcome (Engel’s classification):– Class I (seizure free): 37/69– Class II (some seizures): 8/69– Class III (> 90% reduction): 13/69– Class IV (< 90% reduction): 12/69
Connolly M, et al. Child Nerv Syst. 2006;22:896-908.Madhavan D, et al. Epilepsia. 2007;48:1625-1628.
![Page 23: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/23.jpg)
Sleep Problems in TSC
• Survey of 300 TSC patients (age 0.5-74 years):– 58% with sleep problems in general
• Survey of 40 pediatric TSC patients (age 2-15 yrs):
Hunt A . J Intellectual Disability Res. 1993;37:41-51. Hunt A , Stores G. Dev Med Child Neurol. 1994;36:108-115.
Study Group Sleep Index ± SDTSC children 4.9 ± 3.1Unaffected siblings 0.6 ± 1.0Age/gender-matched controls 0.4 ± 0.7Children with mixed learning disabilities
2.8 ± 2.5
![Page 24: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/24.jpg)
Subependymal Giant Cell Astrocytoma (SEGA)
![Page 25: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/25.jpg)
Acute Hydrocephalus With SEGA
![Page 26: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/26.jpg)
Serial Monitoring for SEGA
![Page 27: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/27.jpg)
Traditional Surgical Resection of SEGA
![Page 28: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/28.jpg)
Stereotactic Angioplasty Balloon Technique
Levine NB, et al. Minim Invasive Neurosurg. 2006;49:317-320.
![Page 29: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/29.jpg)
Genetics of TSC
9 16
TSC1(15%-20%)
TSC2(60%-70%)
PKD1
Autosomal dominantNear 100% penetrance
Variable expression
No Mutation Identified(10%-15%)
![Page 30: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/30.jpg)
TSC1/TSC2 and mTORC1
![Page 31: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/31.jpg)
Rapamycin and Everolimus (RAD001)
Rapamycin(sirolimus)
RAD001(everolimus)
O O OH
O OON
OO
O O
OH
OH
O
O O OH
O OON
OO
O O
O
OH
O
OH
![Page 32: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/32.jpg)
Everolimus and Sirolimus Comparison of PropertiesCharacteristic Everolimus SirolimusMolecular weight (Kd) 958a 914b
Solubility in water (μg/mL) 8-fold higherb 2.6b
Hydrophobicity Lessc Extremeb
Bioavailability (%) ≥ 11a* 1.6e*
Blood:plasma (%) 26% freea
Brain accumulation** 3.1:1f 5.7:1f
Tmax (hrs) 1-2 0.8d
T1/2 (hrs) 30a 86d
Vss (L/kg) 44 -52a 23d
Clearance (mL/hr•kg) 1200a(rat) 256d (man)
a RAD001 Investigators Brochure (6th ed). b Buech G, et al. J Ocul Pharmacol Ther. 2007;23:292.c Formica RN, et al. Transplant Proc. 2004;36(Suppl 25S):495S-499S. d Brattstrom C, et al. Ther Drug Monit. 2000;22:537-544.5. e Kahan BD, et al. Transplantation. 1991;52:185-191. f Serkova N, et al. Br J Pharmacol. 2001;133:875-885.
*Varies with formulation, dose, and co-medications. Everolimus has greater bioavailability than sirolimus.**Ratio of drug in blood (ng/mL) and brain (ng/g) following 6 days oral dosing at 3 mg/kg in rats. f
![Page 33: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/33.jpg)
Rapamycin for Treatment of Angiomyolipoma
A B
Bissler JJ, et al. N Engl J Med. 2008;358:140-151.
![Page 34: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/34.jpg)
Rapamycin Effect on LAM
Bissler JJ, McCormack FX, Young LR, et al. N Engl J Med. 2008;358:140-151.
![Page 35: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/35.jpg)
Rapamycin for the Treatment of SEGA
Franz DN, et al. Ann Neurol. 2006;59:490-498.
![Page 36: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/36.jpg)
Everolimus Effect on SEGA in TSC
Baseline 6 months RAD001
![Page 37: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/37.jpg)
Cerebellar Tuber Growth
![Page 38: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/38.jpg)
Cerebellar Tuber Before and After Treatment With Rapamycin
![Page 39: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/39.jpg)
RAD001 Effect on SEGA Volume
![Page 40: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/40.jpg)
Before Treatment Everolimus x 3 months
Angiomyolipoma Before and After Treatment
![Page 41: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/41.jpg)
Chylothorax in LAM
![Page 42: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/42.jpg)
Current Clinical Trials Related to TSC
• EXIST-1: Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)
• EXIST-2: Efficacy and Safety of RAD001 in Patients 18 Years and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
• MILES: Efficacy and Safety of Rapamycin in Patients with Tuberous Sclerosis Complex Lymphangioleiomyomatosis (TSC-LAM) or Sporadic Lymphangioleiomyomatosis (S-LAM)
• Long-term Follow-Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
• Long-term Follow-Up for RAD001 Therapy of Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex (TSC)
![Page 43: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/43.jpg)
Current Clinical Trials Related to TSC (cont)
• Efficacy and Safety of Aromatase Inhibition for Tuberous Sclerosis Complex Lymphangioleiomyomatosis (TSC-LAM) or Sporadic Lymphangioleiomyomatosis (S-LAM)
• Study of Skin Tumors in Tuberous Sclerosis• Tuberous Sclerosis Complex Natural History Study:
Renal Manifestations• Study of the Disease Process of Lymphangioleiomyomatosis• Effect of Fasting on the Size of Abdominal Lymphatic Tumors
in Women• Role of Genetic Factors in the Development of Lung Disease
![Page 44: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/44.jpg)
Summary
• Tuberous sclerosis is a multiorgan disorder with variable penetrance and severity
• Highest disease morbidity is associated with cerebral, renal, and pulmonary manifestations
• Molecular-based therapies using mTOR inhibitors are showing promise in treating patients with TSC
![Page 45: Ped audio lecture-franz-tsc-4-1](https://reader035.vdocuments.mx/reader035/viewer/2022081413/5492e07ab47959b1078b4749/html5/thumbnails/45.jpg)
Thank you for participatingin this activity.
To proceed to the online CME test, click on the Earn CME Credit link on this page.